Oncodrex’s discovery of unique molecular signatures of metastatic cancers allows the Company to develop targeted therapeutics for those cancers, as well as companion diagnostics to identify patients who will respond to the therapeutics. Combined, this provides a significant differentiator from the current standard of care.
member
Cubresa has installed the first BrainPET Insert System at St. Joseph’s Health Care London, in partnership with the hospital’s research institute – Lawson Health Research Institute.
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.